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Abstract
Valve size selection for transcatheter aortic valve replacement (TAVR) is currently based on cardiac CT-scan. At variance 
with patient-specific computer simulation, this does not allow the assessment of the valve-host interaction. We aimed to 
compare clinical valve size selection and valve size selection by an independent expert for computer simulation. A multicenter 
retrospective analysis of valve size selection by the physician and the independent expert in 141 patients who underwent 
TAVR with the self-expanding CoreValve or Evolut R. Baseline CT-scan was used for clinical valve size selection and for 
patient-specific computer simulation. Simulation results were not available for clinical use. Overall true concordance between 
clinical and simulated valve size selection was observed in 47 patients (33%), true discordance in 15 (11%) and ambiguity in 
79 (56%). In 62 (44%, cohort A) one valve size was simulated whereas two valve sizes were simulated in 79 (56%, cohort B). 
In cohort A, concordance was 76% and discordance was 24%; a smaller valve size was selected for simulation in 10 patients 
and a larger in 5. In cohort B, a different valve size was selected for simulation in all patients in addition to the valve size 
that was used for TAVR. The different valve size concerned a smaller valve in 45 patients (57%) and a larger in 34 (43%). 
Selection of the valve size differs between the physician and the independent computer simulation expert who used the same 
source of information. These findings indicate that valve sizing in TAVR is still more intricate than generally assumed.
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Introduction
Transcatheter aortic valve replacement (TAVR) is an 
accepted treatment in patients with severe aortic stenosis at 
a high or intermediate operative risk [1–5]. At present, dif-
ferent valve types and sizes are available allowing optimal 
transcatheter valve performance and clinical outcome in a 
wide range of patients [5–8]. Availability of different valves 
and sizes implies that choosing the valve that best fits the 
individual patient has become more challenging in particu-
lar as outcome of TAVR depends among others on device-
host interaction. Currently, computed tomography (CT) 
scan of the heart is the standard method and recommended 
for selection of the valve size [9]. Yet, this does not allow 
the prediction of the mechanical interaction and precise 
outcome between the device and host. For that purpose, a 
dedicated computer simulation model has been developed 
and validated to predict case-by-case calcium displacement, 
presence and severity of aortic regurgitation (AR) and con-
duction disturbances post TAVR [10–13]. The purpose of 
this study was to compare transcatheter valve size selection 
between the physician for TAVR and the independent expert 
for the purpose of patient-specific computer simulation.
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Patients and methods
Study population
The study population consisted of 141 patients who had 
undergone TAVR with the self-expanding Medtronic 
valve (CoreValve [MCS] or Evolut R) because of native 
tricuspid aortic stenosis and in whom patient-specific com-
puter simulation was performed for the assessment and 
prediction of valve performance. The information of the 
computer simulation was not available for clinical applica-
tion. The valve size selected for the clinical implantation 
(TAVR) was decided by the physician based upon pre-
procedural multi-slice computed tomography (MSCT) as 
previously described [14]. In all patients and participating 
centers dedicated software (i.e., 3 Mensio, Pie Medical 
Imaging BV, Maastricht, the Netherlands) was used for 
quantitative analysis of the aortic root [15].
All patients provided written informed consent for 
TAVR and data collection. Clinical data was extracted 
from local databases. The study was conducted in accord-
ance with the principles of the Declaration of Helsinki 
and did not fall under the scope of the Medical Research 
Involving Human Subjects Act per EMC Institutional 
Review Board (MEC nr. 2019-0442).
Patient-specific computer simulation was performed 
by an independent institution (FEops, Ghent, Belgium) 
by first creating a virtual model of each patient’s anat-
omy by segmentation and 3D reconstruction of the aor-
tic root (including the calcified native leaflets and out-
flow tract [LVOT]) based on pre-procedural anonymized 
MSCT (Mimics Software, Materialise, Leuven, Belgium) 
[10–13]. All steps performed during TAVR were respected 
during simulation such as eventual pre- or postdilatation 
and valve type (i.e., MCS, Evolut R) but not valve size 
(Abaqus/Explicit finite element solver, Dassault Systèmes, 
Paris, France). The valve size used during simulation was 
decided by the independent simulation expert using the 
aortic annulus dimensions and the manufacturer’s matrix 
of sizing. As the latter contains precise cut-off values for 
each MCS and Evolut R valve size, a margin of ± 2% was 
used for each cut off value (i.e., grey zone of valve size 
selection). In case a patient had an aortic annulus dimen-
sion that falls within the grey zone, 2 sizes were simulated. 
During simulation, 3 levels of depth of implantation were 
executed; 2 mm below the annulus (high implant), 5 mm 
below the annulus (medium depth of implantation) and 
8 mm below the annulus (low implant).
Outcome measures of the simulation were: (1) coronary 
obstruction, (2) aortic regurgitation (AR) and (3) contact 
pressure of the frame within a predefined area below the 
annulus [10–13]. Coronary obstruction was defined by 
measuring the distance between the closest native aortic 
leaflet calcium nodule and the center of the left and right 
coronary ostium post TAVR (i.e., coronary obstruction 
present if distance: 0 mm) [10]. Severity of AR post TAVR 
was measured using computational fluid dynamics and was 
expressed in ml/s. A cut-off value of 16.0 ml/s has been 
reported to correspond to ≥ moderate AR [11]. Contact 
pressure exerted by the frame in the region of the LVOT 
hosting the conduction tissue was expressed as maximum 
contact pressure (MPa) and area (i.e., contact pressure 
index, %). Cut-off values of respectively 0.39 MPa and 
14% were earlier found to correlate with the occurrence 
of new left bundle branch block (LBBB) or high degree 
atrio-ventricular block (high degree AVB) [13].
Clinical outcome measures (after TAVR) were: (1) coro-
nary obstruction defined by TIMI 0 flow during contrast 
angiography immediately post TAVR, (2) AR assessed by 
transthoracic echocardiography before discharge [VARC-2 
criteria, 16] and (3) LBBB or high degree AVB (i.e., Mobitz 
II or 3rd degree AV block) defined by 12-lead ECG before 
discharge [17].
Statistical analysis
The main analysis consisted of the assessment of the agree-
ment between the valve size selected for simulation and 
TAVR and, the comparison between the predicted (simula-
tion) and clinical (TAVR) outcomes, namely (1) coronary 
obstruction, (2) AR and (3) new LBBB or high degree AVB 
in relation to maximum contact pressure and area after 
TAVR. For the purpose of this study, the simulation-derived 
outcome measures at a medium depth of implantation were 
used.
Normality of distributions was tested by the Kolmogo-
rov–Smirnov test. Continuous variables are shown as 
mean ± standard deviation (SD) or medians [interquartile 
ranges (IQR) 25–75%] as appropriate. Categorical variables 
are expressed as frequencies and percentages. Comparison 
between predicted and observed coronary obstruction and 
AR post TAVI (≥ grade 2) was made by means of the McNe-
mar’s test.
Results
Study population
The baseline demographic and procedural characteristics of 
the 141 patients are summarized in Table 1. The median age 
was 82 (78–85) years and 50% were male. In 115 patients 
(82%) a MCS valve was implanted while 26 (18%) received 
an Evolut R valve. With respect to valve size, a 29 mm valve 
was implanted in 92 patients (62%), a 26 mm in 40 (28%) 
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and a 31 mm in 9 (6%). In all patients some degree of over-
sizing was observed, 18 ± 7% when using the perimeter and 
20 ± 7% when using the mean diameter.
Findings
In 62 out of the 141 patients (44%) one valve size was 
simulated (cohort A), 2 valve sizes were simulated in 79 
patients (56%, cohort B). In cohort A (n = 62), concord-
ance (i.e., same valve size selected for simulation and 
TAVR) was 76% (47 patients). Discordance was observed 
in 15 patients (24%, Table 2); a smaller valve was selected 
for simulation in 10 patients and a larger in 5. In cohort 
B (n = 79, Table 3), a different valve size was selected 
for simulation in all patients in addition to the valve size 
that was used for TAVR; a smaller valve was selected for 
simulation in 45 patients (57%) and a larger in 34 (43%). 
This means that overall true concordance (same valve 
size selection for simulation and TAVR by independent 
expert or physician) was observed in 33% of patients, true 
discordance in 11% and ambiguity (i.e., two valve sizes 
selected for simulation and thus a priori considered eligi-
ble for TAVR) in 56% of patients. In case of discordance 
and ambiguity, a smaller valve was used for simulation in 
39% of patients and a larger in 28%. In case of discord-
ant valve size selection in cohort A (n = 15), the degree 
of oversizing was 18 ± 7% when using the perimeter and 
20 ± 7% when using the mean diameter. It was 17 ± 8 and 
15 ± 7%, respectively in cohort B (different valve size used 
for simulation).
Table 1  Baseline, MSCT and 
procedural characteristics
Values are expressed in median (interquartile range), n (%) or mean ± SD
Entire cohort
n = 141
Baseline
 Age (years) 82 (78–85)
 Gender (male) 70 (50)
 Left bundle branch block 15 (11)
 Right bundle branch block 6 (4)
 Pacemaker 15 (11)
Multi-slice computed tomography
 Annulus
  Minimum diameter (mm) 20.5 ± 2.1
  Maximum diameter (mm) 26.8 ± 2.3
  Mean diameter (mm) 23.6 ± 1.9
  Perimeter (mm) 75.5 ± 5.9
  Perimeter derived diameter (mm) 24.0 ± 1.9
  Area  (mm2) 428.9 ± 66.2
  Area derived diameter (mm) 23.3 ± 1.8
Procedural and sizing
 Predilatation 122 (87)
 Predilatation balloon nominal/mean annulus diameter × 100 (%) 90 ± 9
 Valve type
  Medtronic CoreValve 115 (82)
  Medtronic Evolut R 26 (18)
 Valve size
  26 40 (28)
  29 92 (62)
  31 9 (6)
 Valve size/mean annulus diameter × 100 (%) 120 ± 7
 Valve perimeter/perimeter of the annulus × 100 (%) 118 ± 7
 Depth of implantation non coronary cusp 7.2 ± 3.4
 Depth of implantation left coronary cusp 8.3 ± 4.1
 Mean depth of implantation 7.7 ± 3.6
 Postdilatation 13 (9)
 Postdilatation balloon nominal/mean annulus diameter × 100 (%) 105 ± 5
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Outcome cohort A
In correspondence with the clinical observation, simu-
lation did not predict any case of coronary obstruction 
(Table 2). In case of discordant valve size selection, the 
simulation predicted a higher degree of AR post TAVR 
[16.6 (11.3–23.7) ml/s] and (based upon the recently vali-
dated cutoff-value of AR grade ≥ 2) a higher prevalence of 
AR ≥ grade 2 (60%) in comparison with concordant valve 
size selection [14.0 (6.6–24.4) ml/s and 36%), albeit that 
in both situations the predicted AR exceeded the observed 
AR. Predicted AR ≥ grade 2 was significantly higher com-
pared to observed in case of concordant valve size selec-
tion (p = 0.002, Table 2). The predicted maximum contact 
pressure and contact pressure index were lower in case of 
discordant valve size selection (Table 2). The prevalence of 
clinical (i.e., observed) new LBBB and high degree AVB 
after TAVR were similar between con- and discordant valve 
size selection.
Outcome cohort B
Similar to cohort A, coronary obstruction was neither pre-
dicted nor observed (Table 3). In case of simulation of a 
valve size different from TAVR, the simulation predicted 
a higher degree of AR post TAVR [15.4 [7.5–27.5]) ml/s] 
and a higher prevalence of AR ≥ grade 2 (48%) in compari-
son with concordant valve size selection [12.2 (5.1–22.1) 
ml/s and 42%]. Predicted AR ≥ grade 2 was higher than 
observed in both concordant and discordant valve size selec-
tion (respectively p = 0.007 and p = 0.001). No difference in 
predicted maximum contact pressure and contact pressure 
index were seen when using the same or different valve size 
for simulation (Table 3).
Table 2  Outcome in cohort A (simulation of one valve size)
Values are expressed in n (%), median (interquartile range) or mean ± SD
LBBB left bundle branch block, High degree AVB high degree atrio-ventricular block
Concordant clinical valve size and simulated 
valve size n = 47
Discordant clinical valve size and simulated 
valve size n = 15
Predicted Observed p-value Predicted Observed p-value
Coronary obstruction 0 0 – 0 0 –
Aortic regurgitation (ml/s) 14.0 (6.6–24.4) – 16.6 (11.3–23.7) –
Aortic regurgitation ≥ grade 2 17 (36) 4 (9) 0.002 9 (60) 3 (20) 0.07
Maximum contact pressure 0.44 ± 0.25 – 0.33 ± 0.24 –
Maximum contact pressure ≥ 0.39 MPa 24 (51) – 4 (27) –
Contact pressure index 0.21 ± 0.10 – 0.14 ± 0.10 –
Contact pressure index ≥ 14% 35 (75) – 5 (33) –
New LBBB or high degree AVB – 25 (53) – 7 (47)
Table 3  Outcome in cohort B (simulation of two valve sizes)
Values are expressed in n (%), median (interquartile range) or mean ± SD
LBBB left bundle branch block, High degree AVB high degree atrio-ventricular block
Concordant clinical valve size and simulated 
valve size n = 79
Comparison between clinical valve size and 
additional (discordant) simulated valve size 
n = 79
Predicted Observed p-value Predicted Observed p-value
Coronary obstruction 0 0 – 0 0 –
Aortic regurgitation (ml/s) 12.2 (5.1–22.1) – 15.4 (7.5–27.5) –
Aortic regurgitation ≥ grade 2 33 (42) 16 (20) 0.007 38 (48) 16 (20) 0.001
Maximum contact pressure 0.40 ± 0.24 – 0.41 (0.26–0.62) –
Maximum contact pressure ≥ 0.39 MPa 36 (46) – 39 (49) –
Contact pressure index 0.18 ± 0.11 – 0.19 (0.12–0.27) –
Contact pressure index ≥ 14% 49 (62) – 50 (63) –
New LBBB or high degree AVB – 42 (53) – 42 (53)
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Discussion
When comparing valve size selection by the physician 
(using MSCT and dedicated software for quantitative 
analysis of the aortic root) with valve size selection for 
patient-specific computer simulation, we found true con-
cordance in 33% of the patients, true discordance in 11% 
and ambiguity in 56%. Moreover, a smaller valve was 
selected for simulation in 39% of the patients and a larger 
in 28%. These findings indicate that valve size selection in 
TAVR still is more intricate than generally assumed even 
when using MSCT that is the standard imaging modality 
for TAVR planning including valve size selection [9].
These findings need to be interpreted against the follow-
ing; firstly, the physician generally adheres to the cut-off 
values for sizing proposed by the manufacturer’s matrix of 
sizing albeit with some degree of oversizing while a mar-
gin of 2% at each cut-off value in two directions was used 
for the selection of valve size(s) for computer simulation. 
This margin of which its value (i.e., 2%) was arbitrarily 
chosen was introduced as the application of strict cut-off 
criteria in clinical practice is often not realistic or prefer-
able and lacks a sound pathophysiologic basis. The use of 
such a margin or grey zone may explain the observation 
that a smaller valve size was used for simulation in 39% 
of the patients and a larger in 28% in the present analysis.
There are distinct differences between clinical valve 
size selection (physician) and valve size selection based 
upon computer simulation. In the former, the physician 
selects the valve size upon the quantitative assessment of 
the dimensions of the aortic root while in the latter–that 
starts with MSCT analysis–the effects of the device-host 
interaction (e.g., coronary obstruction, AR post TAVR 
and conduction abnormalities) are taken into account. 
The device-host interaction is based upon the integration 
of the dimensions of the device and host and, their bio-
mechanical properties. Tissue biomechanical properties 
are derived from experimental data subsequently refined 
during so-called training of the computer model during 
validation studies [10–13]. Biomechanical properties of 
the frame are derived from standard in vitro testing of the 
stress–strain relationship [18]. Of note, the biomechanical 
properties of the nitinol frame of the herein used valves are 
such that its hysteresis loop has a plateau (i.e., no change 
in radial force during a certain phase of frame compres-
sion or expansion) with some degree of overlap between 
two adjacent valve sizes. This implies that–when a physi-
cian decides to oversize to ensure proper anchoring and to 
avoid PVL–such a strategy does not necessarily translates 
into a higher contact pressure exerted by the frame on the 
LVOT and consequently new conduction abnormalities. 
This is supported by the observation that the predicted 
maximum contact pressure and contact pressure index 
were similar when using the same or different valve size 
for simulation in cohort B. However, a higher predicted 
maximum contact pressure and contact pressure index is 
seen in concordant cohort A versus discordant cohort A 
which we believe is because majority (10/15) of simula-
tions in discordant valve size selection was performed with 
a smaller valve compared to clinical practice. A smaller 
implanted valve is expected to result in less contact pres-
sure. With regard to AR ≥ grade 2, a higher frequency 
was predicted than observed in cohort A (concordant) 
and cohort B (concordant and discordant) which may be 
the result of AR post TAVR quantification by means of 
echocardiography based on the VARC 2 method since it 
is known that echocardiography is inferior to magnetic 
resonance imaging (MRI) for the assessment of AR and 
underestimates the actual degree of AR [19].
The selection of the valve size (and type) that best fits 
the individual patient is mandatory as a patient-specific or 
-tailored approach ensures maximum safety and efficacy. 
This is in particular important with the increasing number 
of sizes and types of valves that are and will be available in 
clinical practice in combination with the fact that the aortic 
root differs from patient to patient. We acknowledge that 
in this analysis, we concentrated on one single valve type 
(i.e., the self-expanding MCS and Evolut R) and did not 
include the balloon-expandable and mechanically expand-
ing valves. Yet, conceptually the role of patient-specific 
computer simulation in clinical practice is self-explanatory. 
This, however, needs to be proven by appropriately designed 
studies such as RCT (physician vs. simulation driven valve 
size and type selection) and implies that the software keeps 
track with the rapid development of novel valve technologies 
and sizes. Given the rapid development of valve technologies 
that effectively address the vexing issues of TAVR (AR in 
particular), patient-specific computer simulation may have 
in particular a clinical value in cases of uncertainty in valve 
size selection for instance due to the strict sizing criteria 
proposed by the manufacturer in combination with observer 
variability in MSCT analysis. It may especially have a clini-
cal added value in the selection of the valve type that best 
fits the individual patient.
Limitations
This study concerns an exploratory analysis of the compari-
son between valve size selection between the physician for 
TAVR and the independent expert for the purpose of patient-
specific computer simulation. The study design consisted of 
a retrospective analysis which may introduce bias. Predicted 
outcomes represent the situation directly post TAVR and no 
conclusions on long term can be drawn based on this study. 
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In addition to the limitations discussed above, the sample 
and the fact that only three centers participated need to be 
considered and affect generalizability.
Conclusion
Selection of the size of the self-expanding valve by the phy-
sician for TAVR and the independent expert for patient-spe-
cific computer simulation differs substantially. Concordance 
was found in only 33% of the patients, true discordance in 
11% and ambiguity in 56%. A smaller valve was selected 
for simulation in 39% of the patients and a larger in 28%. 
These findings indicate that valve sizing in TAVR is still 
more intricate than generally assumed.
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